Abstract
In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.
Keywords: Antagonist therapy, integrin, prostate cancer.
Current Drug Targets
Title:Therapeutic Value of an Integrin Antagonist in Prostate Cancer
Volume: 17 Issue: 3
Author(s): Clément-Lacroix Philippe
Affiliation:
Keywords: Antagonist therapy, integrin, prostate cancer.
Abstract: In recent decades we have seen an exponential interest in the implications of integrin receptors in cancer biology and especially in prostate tumour development. Integrins has been reported to control multiple mechanisms, such as cell survival, proliferation, differentiation, and migration. Here, we report the current understanding of the integrin signalling mechanisms in metastatic prostate tumour development, cross-talks between the primary and metastatic sites on tumour growth, interactions between tumour cells and tissue microenvironment, and epithelial-mesenchymal transition (EMT). Finally, this review presents the integrin-based chemotherapeutic agents currently under clinically consideration and provides an insight into cancer drug development using integrin as a target.
Export Options
About this article
Cite this article as:
Philippe Clément-Lacroix, Therapeutic Value of an Integrin Antagonist in Prostate Cancer, Current Drug Targets 2016; 17 (3) . https://dx.doi.org/10.2174/1389450117666151209115324
DOI https://dx.doi.org/10.2174/1389450117666151209115324 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structural Characterization, Homology Modeling and Docking Studies of ARG674 Mutation in MyH8 Gene Associated with Trismus-Pseudocamptodactyly Syndrome
Letters in Drug Design & Discovery The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility
Current Pharmacogenomics Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Side Effects of Atypical Antipsychotic Drugs
Current Pharmaceutical Design Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Release Characteristics In Vitro and In Vivo of In Situ Gels for a Novel Peptide Compared with Low-Molecular-Weight Hydrophilic Drug
Current Drug Delivery Mannosylated Solid Lipid Nanocarriers of Chrysin to Target Gastric Cancer: Optimization and Cell Line Study
Current Drug Delivery Update of QSAR & Docking & Alignment Studies of the DNA Polymerase Inhibitors
Current Bioinformatics Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Role of Caspases, Bax and Bcl-2 in Chrysin-Induced Apoptosis in the A549 Human Lung Adenocarcinoma Epithelial Cells
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design In vitro Evaluation of Gadolinium-Silica Mesoporous Nanoparticles- Monoclonal Antibody: Potential Nanoprobe for Prostate Cancer Cell Imaging
Current Molecular Imaging (Discontinued) Intracellular Expression of Inflammatory Proteins S100A8 and S100A9 Leads to Epithelial-mesenchymal Transition and Attenuated Aggressivity of Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Hepatitis C Treatment in Patients with Drug Addiction: Clinical Management of Interferon-Alpha-Associated Psychiatric Side Effects
Current Drug Abuse Reviews Radioprotective Effect of Gliclazide as an Anti-Hyperglycemic Agent Against Genotoxicity Induced by Ionizing Radiation on Human Lymphocytes
Cardiovascular & Hematological Agents in Medicinal Chemistry Ellagic Acid: Cytodifferentiating and Antiproliferative Effects In Human Prostatic Cancer Cell Lines
Current Pharmaceutical Design Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry DNA Double Strand Breaks Repair Inhibitors: Relevance as Potential New Anticancer Therapeutics
Current Medicinal Chemistry